WHO ICTRP trial
Optimized sequential therapy versus 10 and 14-day concomitant therapy for…
PACTR202112632957229 · Pan African Clinical Trials Registry (PACTR) · Not Recruiting
Key facts
| Trial ID | PACTR202112632957229 |
|---|---|
| Public title | Optimized sequential therapy versus 10 and 14-day concomitant therapy for eradicating Helicobacter Pylori : A randomized clinical trial |
| Scientific title | Fourteen-day sequential therapy containing Rabeprazole versus 10 and 14-day concomitant therapy in the first line treatment of Helicobacter Pylori infection: A randomized, open-label clinical trial |
| Primary sponsor | Gastroenterology Department of Mohamed V Military Teaching Hospital |
| Registry | Pan African Clinical Trials Registry (PACTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | Morocco |
| Conditions | Digestive System;Digestive System |
| Interventions | Fourteen day quadruple therapy;Ten days quadruple therapy;Optimized sequential therapy |
| Registration date | Nov 25, 2021 |
| Target size | 312 |
| Registry page | pactr.samrc.ac.za |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: